We now have a glimpse behind the curtain of how Medicare arrives at so-called maximum fair prices of prescription drugs it ...

On its last weekday in power, the Biden Administration has chosen the next batch of drugs up for price negotiation in Medicare.

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

The Biden administration has announced the next 15 drugs chosen for Medicare negotiation, marking one of its final acts before President-elect Trump’s inauguration. The Centers for Medicare and ...

Medicare officials say the negotiated prices for these drugs ... The Biden administration announced the 10 drugs selected for the first round of the Medicare Drug Price Negotiation Program in ...

CMS recently issued a statement saying that it's continuing the Medicare Drug Price Negotiation Program but is leaving the door open for potential changes. Experts weighed in on what changes could be ...

Trump could either weaken the negotiations in a way that benefits the pharmaceutical industry, or try to achieve even deeper ...

Pharmacy benefit managers, which negotiate drug prices ... drugs even as more people on Medicare started using them. New prices for the 10 drugs in the first round of price negotiations were ...

The IRA measure is a good first step, but some are looking even further ahead to GLP-1 price drops to increase access.

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will be subject to the next round of Medicare price negotiations, the Biden ...

The executive order, which Biden signed in October 2022, had not spurred any lower drug prices by the time Trump revoked it Jan. 20. The order directed the Health and Human Services Department ...

The Centers for Medicare and Medicaid Services negotiated prices for a first batch of drugs last year — something it could only do because of the Inflation Reduction Act, which passed in 2022.